<DOC>
	<DOCNO>NCT01265615</DOCNO>
	<brief_summary>We hypothesize paricalcitol calcitriol dose-dependent manner effective management chronic allograft dysfunction ( CAD ) , protection repair kidney heart , management chronic renocardiac syndrome ( CRS ) . We assume paricalcitol advantage compare calcitriol cholecalciferol due absence calcemic phosphatemic complication alongside great beneficial potential .</brief_summary>
	<brief_title>Paricalcitol Versus Calcitriol Management Renocardiac Syndrome Renal Transplant Patients</brief_title>
	<detailed_description>Paricalcitol calcitriol identically effective management chronic allograft dysfunction ( CAD ) , protection repair kidney heart , management chronic renocardiac syndrome ( CRS ) . Vitamin D reduce progression CAD . Activation VDR proximal part nephron lead rapid non-genomic beneficial effect urgent multilevel protection functionally important portion kidney . Rising expression VDR distal portion nephron stimulates slow genomic effect local repair response . Hormone D may stimulate recruitment activity different origin stem-progenitor cell ( SPCs ) beneficial effect different stage regeneration force para- autocrine activity . SPCs reveal mostly interstitium among fibroblast-like cell . Vitamin D confirm efficacy tool management mesenchymal stem cell ( MSCs ) human however need research experimental evidence due multifactorial influence SPCs human include immunosuppressive bone-marrow-related effect cyclosporine kidney transplant ( Tx ) patient . Paricalcitol calcitriol slow migration infiltration MSC interstitium vessel wall . The side population mature SPCs ( first , bone-marrow mesenchymal phenotype ) metabolically functionally active portion cell high sensitivity vitamin D receptor ( VDR ) activation responsible repair tissue . The optimal scheme treatment vitamin D patient CAD CRS administration paricalcitol dose 2-4 Î¼g daily supplemental intake vitamin D include special diet , multivitamin , others optimal dose 1800 international unit ( IU ) exclude insolation factor skin carcinoma . High-dose medicinal intake calcitriol ( 6 mcg high ) show relatively high efficacy rather excessive level complication mediate mineral metabolism . Paricalcitol calcitriol may significantly improve contractility myocardium reduce cardiovascular risk , heart failure ( HF ) hypertension beneficial effect cardiorenal axis renin-angiotensin-aldosterone system .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Cardio-Renal Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Age 4075 Male History chronic kidney disease cardiorenal syndrome Written inform consent Female Acute illness Lifethreat competitive illness Mental disorder Endocrinologic disease ( include diabetes mellitus , hyperparathyroidism , thyroid disorder ) Need dialysis Hypercalcemia Concomitant use hormone cytokine medication Participation druginvestigation previous 60 day check VIP check</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>chronic allograft nephropathy</keyword>
	<keyword>stem-progenitor cell</keyword>
	<keyword>cardiorenal syndrome</keyword>
	<keyword>calcitriol</keyword>
	<keyword>paricalcitol</keyword>
	<keyword>cholecalciferol</keyword>
	<keyword>cardiac repair</keyword>
	<keyword>renal repair</keyword>
</DOC>